ArticleThe European respiratory journal2024
Effect of sotatercept on circulating proteomics in pulmonary arterial hypertension.
Abstract readLetter
In one paragraph
Article in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Haemoptysis in chronic pulmonary vascular disease: a narrative review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- ERS Congress 2025: highlights from the Pulmonary Vascular Diseases Assembly.ERJ open research · 2026Article
- Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review.Pulmonary circulation · 2026Review
- Treatment Paradigm Shifts in Pulmonary Arterial Hypertension: Evidence From Asia on Vasodilators to Antiremodeling Therapies.JACC. Asia · 2026Article
- Article
- Sotatercept for the treatment of portopulmonary hypertension: a case report.Communications medicine · 2026Article
- The Vascular-Immune Cells Crosstalk and Microenvironment in Pulmonary Hypertension.Comprehensive physiology · 2026Review
- Sotatercept in Pulmonary Arterial Hypertension: Molecular Mechanisms, Clinical Evidence, and Emerging Role in Reverse Remodelling.International journal of molecular sciences · 2026Review
- Flavonoids: Potential New Drug Candidates for Attenuating Vascular Remodeling in Pulmonary Hypertension.International journal of molecular sciences · 2025Review
- Sotatercept in pulmonary arterial hypertension: revolution, risk and the road ahead.The European respiratory journal · 2025Article
- Progressive Pericardial Effusions (PEF) in Patients With Pulmonary Arterial Hypertension (PAH) Taking Sotatercept-Association With Pre-Existing Pericardial Effusion.Pulmonary circulation · 2025Article
- A Peek into Pulmonary Hypertension through the Plasma Proteome.American journal of respiratory and critical care medicine · 2025Article
- Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome.American journal of respiratory and critical care medicine · 2025Article
- Exploratory Study of Prognostic Plasma Biomarkers in Patients with Pulmonary Arterial Hypertension.The American journal of pathology · 2025Article
- Bone morphogenetic protein-9 controls pulmonary vascular growth and remodeling.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The Role of Somatic Mutation in Hereditary Hemorrhagic Telangiectasia Pathogenesis.Journal of clinical medicine · 2025Review
- Simplifying Sotatercept in Pulmonary Arterial Hypertension: Genetic Context Meets Treatment Response.American journal of respiratory and critical care medicine · 2025Article
- Sotatercept: A Crosstalk Between Pathways and Activities in the Pulmonary Circulation and Blood.International journal of molecular sciences · 2025Review
- ERS Congress 2024: highlights from the Pulmonary Vascular Diseases Assembly.ERJ open research · 2025Article
- Interaction of ferroptosis and cuproptosis in the perspective of pulmonary hypertension.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Laurent SavaleUniversité Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0002-6862-8975
Ly TuUniversité Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0003-2336-5099
Corinne NormandUniversité Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France.
Athénaïs BouclyUniversité Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0001-6246-5557
Olivier SitbonUniversité Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0002-1942-1951
David MontaniUniversité Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0002-9358-6922
Karen M OlssonDepartment for Respiratory Medicine and Infectious Diseases and German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany.
Da-Hee ParkDepartment for Respiratory Medicine and Infectious Diseases and German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany.
Jan FugeDepartment for Respiratory Medicine and Infectious Diseases and German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany.ORCID https://orcid.org/0000-0003-2926-3608
Jan C KampDepartment for Respiratory Medicine and Infectious Diseases and German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany.ORCID https://orcid.org/0000-0002-5002-409X
Marc HumbertUniversité Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0003-0703-2892
Marius M HoeperDepartment for Respiratory Medicine and Infectious Diseases and German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany.ORCID https://orcid.org/0000-0001-9086-2293
Christophe GuignabertUniversité Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France christophe.guignabert@inserm.fr.ORCID https://orcid.org/0000-0002-8545-4452
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.